High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo
Anoumou Y. Dagnra,Nicole Vidal,Akovi Mensah,Akouda Patassi,Komi Aho,Mounerou Salou,Marjorie Monleau,Mireille Prince-David,Assétina Singo,Palokinam Pitché,Eric Delaporte,Martine Peeters +11 more
Reads0
Chats0
TLDR
The high number of resistant strains observed in Togo shows clearly that the emergence of HIV drug resistance is of increasing concern in countries where ART is now widely used, and can compromise the long-term success of first- and second-line ART.Abstract:
With widespread use of antiretroviral (ARV) drugs in Africa, one of the major potential challenges is the risk of emergence of ARV drug-resistant HIV strains. Our objective is to evaluate the virological failure and genotypic drug-resistance mutations in patients receiving first-line highly active antiretroviral therapy (HAART) in routine clinics that use the World Health Organization public health approach to monitor antiretroviral treatment (ART) in Togo.read more
Citations
More filters
Journal ArticleDOI
Development of Nevirapine Resistance in Children Exposed to the Prevention of Mother-to-Child HIV-1 Transmission Programme in Maputo, Mozambique.
Francisco Antunes,Pereira Zindoga,Perpétua Gomes,Orvalho Augusto,Isabel Mahumane,Luis Veloso,Emília Valadas,Ricardo Jorge Camacho +7 more
TL;DR: A high prevalence of NVP RAM is found among children who were exposed to the drug regimen for PMTCT in Mozambique and the mother’s exposure to PMT CT significantly increased the risk of N VP RAM.
Journal ArticleDOI
Drug resistance mutations and genetic diversity in adults treated for HIV type 1 infection in Mauritania.
F-Zahra Fall-Malick,Edmond Tchiakpe,Sid'Ahmed Ould Soufiane,Halimatou Diop-Ndiaye,Abderrahmane Mouhamedoune Baye,Abdallah Ould Horma Babana,Coumba Toure Kane,Baidy Lo,Souleymane Mboup +8 more
TL;DR: A high rate of DRM was found in this study and shows the potential need for a structured virological surveillance including viral load quantification and genotyping and the great variability of HIV‐1 strains in Mauritania.
Journal ArticleDOI
High efficacy of first-line ART in a West African cohort, assessed by dried blood spot virological and pharmacological measurements.
Pierre de Truchis,Minh Patrick Lê,M Daou,Boubacar Madougou,Yacouba Nouhou,Sahada Moussa Saley,Achirou Sani,Eric Adehossi,Elisabeth Rouveix,Mamadou Saidou,Gilles Peytavin,Constance Delaugerre +11 more
TL;DR: This study demonstrated a good response after 4 years of first-line ART in Niger, and the majority of failures were explained by selection of drug resistance mutations detected in the DBS genotype.
Journal ArticleDOI
Virological outcome among HIV-1 infected patients on first-line antiretroviral treatment in semi-rural HIV clinics in Togo.
Abla A. Konou,Mounerou Salou,Nicole Vidal,Pascal Kodah,Damobé Kombate,Pyabalo Kpanla,Tchabia Nabroulaba,Djifa Nyametso,Assetina Singo-Tokofaï,Palokinam Pitché,Eric Delaporte,Mireille Prince-David,Martine Peeters,Anoumou Y. Dagnra +13 more
TL;DR: The observations on ART treatment outcome from ART clinics in semi-rural areas are close to previous observations in Lomé, the capital city suggesting that national ART-programme management plays a role in treatment outcome.
Journal ArticleDOI
Optimizing Treatment Switch for Virologic Failure during First-Line Antiretroviral Therapy in Resource-Limited Settings
Adedotun A. Adetunji,Chad J. Achenbach,Joe Feinglass,Kristin M. Darin,Kimberly K. Scarsi,Ernest Ekong,Babafemi Taiwo,Isaac F. Adewole,Robert L. Murphy +8 more
TL;DR: The maximum permissible time between suspicion of virologic failure and completion of antiretroviral treatment switch should not exceed 6 months when patients develop first-line antireTroviral failure in resource-limited settings.
References
More filters
Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision.
TL;DR: These guidelines are primarily intended for use by national and regional HIV programme managers managers of nongovernmental organizations delivering HIV care services and other policy-makers who are involved in the scaling up of comprehensive HIV care and ART in resource-limited countries.
Journal ArticleDOI
Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.
Paula Braitstein,Mwg Brinkhof,François Dabis,Mauro Schechter,Andrew Boulle,Paolo G. Miotti,Robin Wood,Christian Laurent,Eduardo Sprinz,Catherine Seyler,David R. Bangsberg,Eric Balestre,Jonathan A C Sterne,Margaret T May,Matthias Egger +14 more
TL;DR: Patients starting HAART in resource-poor settings have increased mortality rates in the first months on therapy, compared with those in developed countries, and timely diagnosis and assessment of treatment eligibility, coupled with free provision of HAART might reduce this excess mortality.
Journal ArticleDOI
The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings
Charles F. Gilks,Siobhan Crowley,Rene Ekpini,Sandy Gove,Jos Perriens,Yves Souteyrand,Don Sutherland,Marco Vitoria,Teguest Guerma,Kevin M. De Cock +9 more
TL;DR: A public-health approach to antiretroviral therapy (ART) to enable scaling-up access to treatment for HIV-positive people in developing countries, recognising that the western model of specialist physician management and advanced laboratory monitoring is not feasible in resource-poor settings.
Journal ArticleDOI
Efficacy of Antiretroviral Therapy Programs in Resource-Poor Settings: A Meta-analysis of the Published Literature
TL;DR: ART treatment programs in resource-poor settings have efficacy rates similar to those reported for developed countries, and the provision of medications free of charge to the patient is associated with a significantly increased probability of virologic suppression at months 6 and 12 of ART.
Journal ArticleDOI
Darunavir: pharmacokinetics and drug interactions.
TL;DR: Reports from resource-limited countries suggest that initial ART programmes are as effective as in resource-rich countries, which should limit HIV drug resistance if programme effectiveness continues during scale-up.